Clinical Trial: The Effect of Bevacizumab (Avastin) on Pterygium
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: The Effect of Bevacizumab (Avastin) on Pterygium
Brief Summary: The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.
Detailed Summary:
Sponsor: University of Alabama at Birmingham
Current Primary Outcome: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. [ Time Frame: Baseline and 3 months ]
Growth of the pterygium was defined as an increase in the area of the pterygium as measured from the limbus toward the visual axis. This would be a positive change value indicating progression
Regression of the pterygium was defined as a decrease in the area of the pterygium length measured from the limbus toward the visual axis. This would be negative change value indicating regression.
Original Primary Outcome: To determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth [ Time Frame: 6 months ]
Current Secondary Outcome: Number of Patients Having Surgical Removal of Pterygium. [ Time Frame: 12 months ]
Original Secondary Outcome: Limiting the need for surgery [ Time Frame: 12 months ]
Information By: University of Alabama at Birmingham
Dates:
Date Received: December 26, 2007
Date Started: August 2007
Date Completion:
Last Updated: May 20, 2014
Last Verified: May 2012
